Board of the Pension Protection Fund Invests $989,000 in Cencora, Inc. (NYSE:COR)

Board of the Pension Protection Fund purchased a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,400 shares of the company's stock, valued at approximately $989,000. Cencora makes up 1.1% of Board of the Pension Protection Fund's portfolio, making the stock its 25th biggest position.

A number of other large investors also recently bought and sold shares of the stock. Concord Wealth Partners purchased a new position in Cencora during the third quarter worth approximately $30,000. SYSTM Wealth Solutions LLC purchased a new position in shares of Cencora during the 2nd quarter valued at approximately $36,000. Ashton Thomas Securities LLC acquired a new stake in Cencora in the 3rd quarter valued at $41,000. Fairscale Capital LLC purchased a new stake in Cencora in the 2nd quarter worth $54,000. Finally, Modus Advisors LLC acquired a new position in Cencora during the fourth quarter worth $54,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on COR. Bank of America reiterated a "neutral" rating and issued a $245.00 target price (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Evercore ISI boosted their price objective on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Robert W. Baird raised their target price on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Finally, Leerink Partners decreased their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $275.60.

Cencora Trading Down 1.0 %

Shares of NYSE COR traded down $2.31 during mid-day trading on Wednesday, reaching $237.74. 1,186,513 shares of the company's stock were exchanged, compared to its average volume of 1,303,101. The company's 50-day moving average is $237.95 and its 200-day moving average is $233.65. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market capitalization of $45.95 billion, a price-to-earnings ratio of 31.66, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $253.27.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio (DPR) is 29.29%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 94,696 shares of company stock worth $22,862,734 over the last three months. Insiders own 15.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.